Proton Pump Inhibitors in Children: the Good, the Bad, and the Ugly

Abstract

Purpose of Review

The evidence supporting or contesting the prescription of proton pump inhibitors (PPIs) for children and updates on side effects are reviewed.

Recent Findings

PPIs remain an important therapeutic option for esophagitis and gastritis. However, recent studies demonstrate no benefit when prescribing PPIs for chronic cough, infantile reflux, asthma, or functional gastrointestinal disorders. Recent studies suggest adverse effects on microbiome diversity and immune function, resulting in increased rates of gastrointestinal infections, bone fractures, and atopic disorders. PPIs influence a variety of cell types within the in the innate and adaptive immune systems.

Summary

PPI prescriptions in children may be indicated for select conditions; however, multiple side effects and immune effects have been described. While most of these side effects are rare and mild, some studies suggest enduring adverse effects. Future studies to elucidate the mechanism behind some of these immune and infectious complications will be beneficial.

This is a preview of subscription content, log in to check access.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45(4):421–7.

    CAS  Google Scholar 

  2. 2.

    De Bruyne P, Ito S. Toxicity of long-term use of proton pump inhibitors in children. Arch Dis Child. 2018;103(1):78–82.

    Google Scholar 

  3. 3.

    Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early acid suppression therapy exposure and fracture in young children. Pediatrics. 2019;144(1):e20182625.

    Google Scholar 

  4. 4.

    Yadlapati R, Kahrilas PJ. The “dangers” of chronic proton pump inhibitor use. J Allergy Clin Immunol. 2018;141(1):79–81.

    Google Scholar 

  5. 5.

    Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15.

    CAS  Google Scholar 

  6. 6.

    •• Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022–33.e10. Most recent EoE guidelines.

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, et al. The appropriate use of proton-pump inhibitors. Minerva Med. 2018;109(5):386–99.

    Google Scholar 

  8. 8.

    Stark CM, Nylund CM. Side effects and complications of proton pump inhibitors: a pediatric perspective. J Pediatr. 2016;168:16–22.

    Google Scholar 

  9. 9.

    Chung EY, Yardley J. Are there risks associated with empiric acid suppression treatment of infants and children suspected of having gastroesophageal reflux disease? Hosp Pediatr. 2013;3(1):16–23.

    Google Scholar 

  10. 10.

    Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol. 2015;80(2):200–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    •• Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):516–54. NASPGHAN guideline with age-based algorithm for GERD management.

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    Helin N, Kolho K, Rintala R, Merras-Salmio L. Upper endoscopy for non-acute non-specific symptoms is seldom beneficial for children under the age of seven. Acta Paediatr. 2020;109(4):827–35.

    Google Scholar 

  13. 13.

    Saito T, Uesato M, Terui K, Nakata M, Komatsu S, Yoshida H. Acid and bolus exposure in pediatric reflux disease according to the presence and severity of esophageal mucosal lesions. Pediatr Surg Int. 2019;35(8):887–93.

    Google Scholar 

  14. 14.

    Tolia V, Youssef NN, Gilger MA, Traxler B, Illueca M. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. J Pediatr Gastroenterol Nutr. 2015;60:S24–30.

    Google Scholar 

  15. 15.

    Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20.

    Google Scholar 

  16. 16.

    Ruffner MA, Spergel JM. Eosinophilic esophagitis in children. Curr Allergy Asthma Rep. 2017;17(8):54.

    Google Scholar 

  17. 17.

    Dobbins JW, Sheahan DG, Behar J. Eosinophilic gastroenteritis with esophageal involvement. Gastroenterology. 1977;72(6):1312–6.

    CAS  Google Scholar 

  18. 18.

    Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319–32.

    Google Scholar 

  19. 19.

    Shaheen NJ, Mukkada V, Eichinger CS, Schofield H, Todorova L, Falk GW. Natural history of eosinophilic esophagitis: a systematic review ofepidemiology and disease course. Dis Esophagus. 2018;31(8):doy015.

  20. 20.

    Rubinstein E, Rosen R. Respiratory symptoms associated with eosinophilic esophagitis. Pediatr Pulmonol. 2018;53(11):1587–91.

    Google Scholar 

  21. 21.

    Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22.e1.

    CAS  Google Scholar 

  22. 22.

    Min SB, Nylund CM, Baker TP, Ally M, Reinhardt B, Chen YJ, et al. Longitudinal evaluation of noninvasive biomarkers for eosinophilic esophagitis. J Clin Gastroenterol. 2017;51(2):127–35.

    Google Scholar 

  23. 23.

    Dellon ES, Speck O, Woodward K, Covey S, Rusin S, Gebhart JH, et al. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study. Clin Gastroenterol Hepatol. 2014;12(12):2015–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Park JY, Zhang X, Nguyen N, Souza RF, Spechler SJ, Cheng E. Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia. PLoS One. 2014;9(7):e101391.

    PubMed  PubMed Central  Google Scholar 

  25. 25.

    Molina-Infante J, Rivas MD, Hernandez-Alonso M, Vinagre-Rodríguez G, Mateos-Rodríguez JM, Dueñas-Sadornil C, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40(8):955–65.

    CAS  Google Scholar 

  26. 26.

    Zhang X, Cheng E, Huo X, Yu C, Zhang Q, Pham TH, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One. 2012;7(11):e50037.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Cheng E, Zhang X, Wilson KS, Wang DH, Park JY, Huo X, et al. JAK-STAT6 pathway inhibitors block eotaxin-3 secretion by epithelial cells and fibroblasts from esophageal eosinophilia patients: promising agents to improve inflammation and prevent fibrosis in EoE. PLoS One. 2016;11(6):e0157376.

    PubMed  PubMed Central  Google Scholar 

  28. 28.

    Garza JM, Nylund CM, Kaul A. Time to stop blaming gastroesophageal reflux. Clin Pediatr (Phila). 2011;50(12):1110–5.

    Google Scholar 

  29. 29.

    Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514–20.

    CAS  Google Scholar 

  30. 30.

    De Bruyne P, Christiaens T, Vander Stichele R, Van Winckel M. Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: analysis of the national database, [1997-2009]. J Pediatr Gastroenterol Nutr. 2014;58(2):220–5.

    Google Scholar 

  31. 31.

    Chen X, Peng WS, Wang L. Etiology analysis of nonspecific chronic cough in children of 5 years and younger. Medicine (Baltimore). 2019;98(3):e13910.

    Google Scholar 

  32. 32.

    Adamko DJ, Majaesic CM, Skappak C, Jones AB. A pilot trial on the treatment of gastroesophageal reflux-related cough in infants. Transl Pediatr. 2012;1(1):23–34.

    PubMed  PubMed Central  Google Scholar 

  33. 33.

    Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, et al. Randomized clinical trial of lansoprazole for poorly controlled asthma in children: the American Lung Association Asthma Clinical Research Centers. JAMA. 2012;307(4):373–81.

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    • Duncan DR, Mitchell PD, Larson K, ME MS, Rosen RL. Association of PPI with hospitalization risk in children with oropharyngeal dysphagia. JAMA Otolaryngol Head Neck Surg. 2018;144(12):1116–24. Excellent article from an aerodigestive clinic experience discussing association between PPI use and hospitalization risk.

    PubMed  PubMed Central  Google Scholar 

  35. 35.

    • Chang AB, Oppenheimer JJ, Kahrilas PJ, Kantar A, Rubin BK, Weinberger M, et al. Chronic cough and gastroesophageal reflux in children: chest guideline and expert panel report. Chest. 2019;156(1):131–40. Guidelines from CHEST for testing and management of cough and GERD in children.

    Google Scholar 

  36. 36.

    Fracchia MS, Diercks G, Cook A, Hersh C, Hardy S, Hartnick M, et al. The diagnostic role of triple endoscopy in pediatric patients with chronic cough. Int J Pediatr Otorhinolaryngol. 2019;116:58–61.

    Google Scholar 

  37. 37.

    Bokulich NA, Chung J, Battaglia T, Henderson N, Jay M, Li H, et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci Transl Med. 2016;8(343):343ra82.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Kato LM, Kawamoto S, Maruya M, Fagarasan S. The role of the adaptive immune system in regulation of gut microbiota. Immunol Rev. 2014;260(1):67–75.

    CAS  Google Scholar 

  39. 39.

    Zhang H, Sparks JB, Karyala SV, Settlage R, Luo XM. Host adaptive immunity alters gut microbiota. ISME J. 2015;9(3):770–81.

    CAS  Google Scholar 

  40. 40.

    Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8.

    CAS  Google Scholar 

  41. 41.

    Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Schwartz NRM, Hutfless S, Herrinton LJ, Amsden LB, Fevrier HB, Giefer M, et al. Proton pump inhibitors, H2 blocker use, and risk of inflammatory bowel disease in children. J Pediatr Pharmacol Ther. 2019;24(6):489–96.

    PubMed  PubMed Central  Google Scholar 

  43. 43.

    Maruvada P, Leone V, Kaplan LM, Chang EB. The human microbiome and obesity: moving beyond associations. Cell Host Microbe. 2017;22(5):589–99.

    CAS  Google Scholar 

  44. 44.

    Stark CM, Susi A, Emerick J, Nylund CM. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut. 2018;68(1):62–9.

    Google Scholar 

  45. 45.

    Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11):1269–81.

    CAS  Google Scholar 

  46. 46.

    Tennant SM, Hartland EL, Phumoonna T, Lyras D, Rood JI, Robins-Browne RM, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76(2):639–45.

    CAS  Google Scholar 

  47. 47.

    Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55(9):2431–40.

    CAS  Google Scholar 

  48. 48.

    FDA. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). RDA Drug Safety Communication. 2012. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-clostridium-difficile-associated-diarrhea-can-be-associated-stomach. Accessed 03 Apr 2020.

  49. 49.

    Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    •• Anjewierden S, Han Z, Foster CB, Pant C, Deshpande A. Risk factors for Clostridium difficile infection in pediatric inpatients: a meta-analysis and systematic review. Infect Control Hosp Epidemiol. 2019;40(4):420–6. Meta-analysis of over 10,000 cases demonstrating increased odds forClostridium difficileinfection when PPI is prescribed to children.

    Google Scholar 

  51. 51.

    Garcia Rodriguez LA, Ruigomez A, Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5(12):1419–23.

    Google Scholar 

  52. 52.

    Thachil J. Overprescribing PPIs: time for a hospital antacid policy on Clostridium difficile. BMJ. 2008;336(7636):109.

    PubMed  PubMed Central  Google Scholar 

  53. 53.

    Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. Epidemiol Infect. 2017;145(8):1617–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Vilcu AM, Sabatte L, Blanchon T, Souty C, Maravic M, Lemaitre M, et al. Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses. JAMA Netw Open. 2019;2(11):e1916205.

    PubMed  PubMed Central  Google Scholar 

  55. 55.

    Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.

    PubMed  PubMed Central  Google Scholar 

  56. 56.

    Zirk-Sadowski J, Masoli JA, Delgado J, Hamilton W, Strain WD, Henley W, et al. Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults. J Am Geriatr Soc. 2018;66(7):1332–8.

    PubMed  PubMed Central  Google Scholar 

  57. 57.

    Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117(5):e817–20.

    Google Scholar 

  58. 58.

    •• Velasco-Benitez CA. Proton pump inhibitors and infant pneumonia/other lower respiratory tract infections: national nested case-control study. J Pediatr Gastroenterol Nutr. 2019;68(1):e19. Pediatric data on CAP and PPI is sparse, but this 2019 case-control study of 631 infants found no assocation between PPI use and respiratory tract infections.

    Google Scholar 

  59. 59.

    Lin SM, Yang SH, Liang CC, Huang HK. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int. 2018;29(1):153–62.

    CAS  Google Scholar 

  60. 60.

    Fattahi MR, Niknam NR, Shams M, Anushiravani A, Taghavi SA, Omrani GR, et al. The association between prolonged proton pump inhibitors use and bone mineral density. Risk Manag Healthc Policy. 2019;12:349–55.

    PubMed  PubMed Central  Google Scholar 

  61. 61.

    Poly TN, Islam MM, Yang HC, Wu CC, Li YJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103–14.

    CAS  Google Scholar 

  62. 62.

    Freedberg DE, Haynes K, Denburg MR, Zemel BS, Leonard MB, Abrams JA, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos Int. 2015;26(10):2501–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Otani I, Banerji A. Immediate and delayed hypersensitivity reactions to proton pump inhibitors: evaluation and management. Curr Allergy Asthma Rep. 2016;16(3):17.

    Google Scholar 

  64. 64.

    Casciaro M, Navarra M, Inferrera G, Liotta M, Gangemi S, Minciullo PL. PPI adverse drugs reactions: a retrospective study. Clin Mol Allergy. 2019;17(1).

  65. 65.

    Barakat L, Vasconcelos MJ, Bourrain JL, Demoly P, Chiriac AM. IgE mediated allergy to proton pump inhibitors with both delayed and immediate onset. Asia Pac Allergy. 2019;14(9):e30.

    Google Scholar 

  66. 66.

    •• Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. Ann Allergy Asthma Immunol. 2013;111(6):452–7. Comprehensive literature review of PPI-mediated hypersensitivity reactions includes clinical characteristics, reaction categorization, and an evidence-based algorithm for evaluation and treatment.

    CAS  Google Scholar 

  67. 67.

    Mota I, Gaspar A, Chambel M, Morais-Almeida M. Anaphylaxis induced by proton pump inhibitors. J Allergy Clin Immunol Pract. 2016;4(3):535–6.

    Google Scholar 

  68. 68.

    Tayman C, Mete E, Catal F, Tonbul A. Hypersensitivity reaction to omeprazole in a child. J Investig Allergol Clin Immunol. 2009;19(1):76–7.

    CAS  Google Scholar 

  69. 69.

    Lin CY, Wang CW, Hui CR, Chang YC, Yang CH, Cheng CY, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T-cell reactivity study. Allergy. 2018;73(1):221–9.

    CAS  Google Scholar 

  70. 70.

    Hait EJ, McDonald DR. Impact of gastroesophageal reflux disease on mucosal immunity and atopic disorders. Clin Rev Allergy Immunol. 2019;57(2):213–25.

    Google Scholar 

  71. 71.

    Jordakieva G, Kundi M, Untersmayr E, Pali-Scholl I, Reichardt B, Jensen-Jarolim E. Country-wide medical records infer increased allergy risk of gastric acid inhibition. Nat Commun. 2019;10:3298.

    PubMed  PubMed Central  Google Scholar 

  72. 72.

    •• Untersmayr E, Bakos N, Scholl I, Kundi M, Roth-Walter F, Szalai K, et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB. 2005;19(6):656–8. Only study thus far to investigate relative changes and new IgE formation to foods before and after chronic PPI use, suggest PPIs may have a role in development of ingsted food sensitization.

    CAS  Google Scholar 

  73. 73.

    •• Mitre E, Susi A, Kropp LE, Schwartz DJ, Gorman GH, Nylund CM. Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood. JAMA Pediatr. 2018;172(6):e180315. This 2019 study identified multiple associations between PPI use and allergic disorders in a large pediatric cohort.

    PubMed  PubMed Central  Google Scholar 

  74. 74.

    Andersen AB, Erichsen R, Farkas DK, Mehnert F, Ehrenstein V, Sørensen HT. Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study. Aliment Pharmacol Ther. 2012;35(10):1190–8.

    CAS  Google Scholar 

  75. 75.

    Mulder B, Schulling-Veninga CC, Bos HJ, De Vries TW, Jick SS, Hak E. Prenatal exposure to acid-suppressive drugs and the risk of allergic diseases in the offspring: a cohort study. Clin Exp Allergy. 2014;44(2):261–9.

    CAS  Google Scholar 

  76. 76.

    Soriano Cea L, Hernandez-Diaz S, Johansson S, Nagy P, Garcia-Rodriguez LA. Exposure to acid-suppressive drugs during pregnancy and the risk of asthma in childhood: an observational cohort study. Aliment Pharmacol Ther. 2016;43(3):427–37.

    Google Scholar 

  77. 77.

    Yitshak-Sade M, Gorodischer R, Aviram M, Novack L. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. J Clin Pharmacol. 2016;56(1):116–23.

    CAS  Google Scholar 

  78. 78.

    • Lai T, Wu M, Liu J, Juo M, He L, Wang X, et al. Acid-suppressive drug use during risk of pregnancy and the risk of childhood asthma: a meta-analysis. Pediatrics. 2018;141(2):e20170889. Large meta-analysis identifying a significant association between maternal PPI use during pregnancy and the development of asthma in offspring.

    Google Scholar 

  79. 79.

    Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–22.

    CAS  Google Scholar 

  80. 80.

    Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors – inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14:74–81.

    CAS  Google Scholar 

  81. 81.

    Capodicasa E, Comacchione P, Natalini B, Bartoli A, Coaccioli S, Marconi P, et al. Omeperazole induces apoptosis in normal human polymorphonuclear leukocytes. Int J Immunopathol Pharmacol. 2008;21(1):73–85.

    CAS  Google Scholar 

  82. 82.

    Ubagai T, Koshibu Y, Koshio O, Nakaki T, Ono Y. Downregulation of immunomodulator gene expression in LPS-stimulated human polymorphonuclear leukocytes by the proton pump inhibitor lansoprazole. J Infect Chemother. 2009;15(6):374–9.

    CAS  Google Scholar 

  83. 83.

    Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of clinical implications. Dig Dis Sci. 2009;54(11):2312–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Alkim H, Unai S, Okur H, Imir T. Omeprazole inhibits natural killer cell functions. Dig Dis Sci. 2008;53(2):347–51.

    CAS  Google Scholar 

  85. 85.

    Capodicasa E, De Bellis F, Pelli MA. Effect of lansoprazole on human leukocyte function. Immunopharmacol Immunotoxicol. 1999;21(2):357–77.

    CAS  Google Scholar 

  86. 86.

    Ohara T, Arakawa T. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci. 1999;44(8):1710–5.

    CAS  Google Scholar 

  87. 87.

    Hinoki A, Yoshimura K, Fujita K, Akita M, Ikeda R, Nagashima M, et al. Suppression of proinflammatory cytokine production in macrophages by lansoprazole. Pediatr Surg Int. 2006;22(11):915–23.

    Google Scholar 

  88. 88.

    Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, et al. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol. 2013;48(12):1343–52.

    Google Scholar 

  89. 89.

    Berney-Meyer L, Hung N, Slatter T, Schollum JB, Kitching AR, Walker RJ. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury? Nephrology (Carlton). 2014;19(6):359–65.

    CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Cade M. Nylund.

Ethics declarations

Conflict of Interest

This work was prepared as part of the official duties of Drs. Pasman, Witmer, Ong, and Nylund, who are employed by the United States Navy, Army, and Air Force. The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Navy, Army, Air Force, Department of Defense, The Uniformed Services of the Health Sciences or the United States Government.

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Allergy and Immunology

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pasman, E.A., Ong, B., Witmer, C.P. et al. Proton Pump Inhibitors in Children: the Good, the Bad, and the Ugly. Curr Allergy Asthma Rep 20, 39 (2020). https://doi.org/10.1007/s11882-020-00926-4

Download citation

Keywords

  • Proton pump inhibitor
  • Children
  • Allergy
  • Immunology
  • Side effects